Cue Biopharma has been granted a patent for variant immunomodulatory polypeptides and fusion polypeptides, including T-cell modulatory multimeric polypeptides. The patent also covers nucleic acids encoding these polypeptides and methods for modulating T cell activity. GlobalData’s report on Cue Biopharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights Cue Biopharma Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Cue Biopharma, CAR-T cell based therapies was a key innovation area identified from patents. Cue Biopharma's grant share as of February 2024 was 11%. Grant share is based on the ratio of number of grants to total number of patents.

Fusion polypeptide with variant il-2 and antibody fc region

Source: United States Patent and Trademark Office (USPTO). Credit: Cue Biopharma Inc

A recently granted patent (Publication Number: US11905320B2) discloses a fusion polypeptide comprising a variant IL-2 polypeptide with up to five amino acid substitutions and an antibody Fc region. The fusion polypeptide ranges from 300 to 700 amino acids and does not include a major histocompatibility complex (MHC) polypeptide. Additionally, the patent specifies variations in the amino acid sequence of the antibody Fc region, ensuring at least 95% sequence identity to a specific reference sequence (SEQ ID NO: 57) with specific amino acid substitutions.

Furthermore, the patent claims cover fusion polypeptides with different ranges of amino acids, from 300 to 700, and variations in the IL-2 polypeptide with up to four amino acid substitutions. The fusion polypeptides also include a heterologous fusion partner, comprising an antibody Fc region and an antigen-binding region of an antibody. The patent emphasizes the exclusion of major histocompatibility complex (MHC) polypeptides in these fusion polypeptides and highlights the specific amino acid substitutions in the Ig Fc region. Overall, the patent provides a detailed description of the fusion polypeptides, their components, and variations, aiming to protect the intellectual property associated with these novel compositions.

To know more about GlobalData’s detailed insights on Cue Biopharma, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies